Fosgonimeton

Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models[1][2][3][4].

Product Specifications

CAS Number

[2093305-05-4]

Product Name Alternative

ATH-1017

UNSPSC

12352005

Hazard Statement

H302, H311, H314, H411

Target

C-Met/HGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/fosgonimeton.html

Purity

98.24

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=P(O)(O)OC(C=C1)=CC=C1C[C@H](NC(CCCCC)=O)C(N[C@@H]([C@@H](C)CC)C(NCCCCCC(N)=O)=O)=O

Molecular Formula

C27H45N4O8P

Molecular Weight

584.64

Precautions

H302, H311, H314, H411

References & Citations

[1]Leen H. KAWAS, et al. WO2017210489. 2021.|[2]Reda SM, et al. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 2024 Jul;21 (4) :e00350. |[3]Johnston JL, et al. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023 Mar;20 (2) :431-451.|[4]Reda S, et al. Fosgonimeton, a novel, small molecule positive modulator of the HGF/MET system is neuroprotective in primary neuron culture. Alzheimer's Dement. 2022 18: e065874.